[go: up one dir, main page]

AR059246A1 - Compuestos heterobiciclicos de tiofeno y metodos de uso - Google Patents

Compuestos heterobiciclicos de tiofeno y metodos de uso

Info

Publication number
AR059246A1
AR059246A1 ARP070100391A ARP070100391A AR059246A1 AR 059246 A1 AR059246 A1 AR 059246A1 AR P070100391 A ARP070100391 A AR P070100391A AR P070100391 A ARP070100391 A AR P070100391A AR 059246 A1 AR059246 A1 AR 059246A1
Authority
AR
Argentina
Prior art keywords
nr10r11
aryl
alkyl
cr14r15
heteroaryl
Prior art date
Application number
ARP070100391A
Other languages
English (en)
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR059246A1 publication Critical patent/AR059246A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Compuesto de formula (1) y sus sales farmacéuticamente aceptables, que son utiles para inhibir las quirosin quinasas receptoras y para tratar trastornos intermediados por éstas. Se describen métodos de uso de los compuestos de formula (1) y sus sales farmacéuticamente aceptables para el diagnostico, prevencion o tratamiento in vitro, in situ e in vivo de dichos trastornos en células de mamíferos o trastornos patologicos asociados. Reivindicacion 1: Un compuesto seleccionado de la formula (1), y sus sales farmacéuticamente aceptables, donde: X es O, S o NR10; Z2 y Z3 están independientemente seleccionados entre CR4 y N, donde unicamente uno de Z2 y Z3 es N; R1 es H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, -C(=O)NR10R11, N- (CR14R15)tNR10R11, -NR10C(=Y)R11, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, o -NR12SO2NR10R11, o R1 es un carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20 monocíclico o bicíclico, donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, CN, CF3, oxo, OR10, SR10, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -(CR14R15)n-NR10R11, - NR10C(=Y)R13, -NR10C(=Y)OR11, --NR12C(=Y)NR10R11, -NR12SO2R10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, -SC(=Y)OR10, - SC(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, -(CR14R15)n-NR12C(=O)(CR14R15)mNR10R11, y -C(O)(CR14R15)nNR10R11; R2 y R4 son independientemente H, F, CI, Br, I, CN, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -NR10R11, -NR10C(=Y)R11, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12SO2R10R11, -OR10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -C(=O)NR12(CR14R15)tNR10R11, -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -SR10, -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20, donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, OR10, y NR10R11; R3 es un carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20 monocíclicos o bicíclicos, donde dichos carbociclilo, heterociclilo, arilo y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, CN, CF3, OR10, SR10, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -NR10R11, - NR10C(=Y)R13, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12C(=Y)NR10R11, -NR12C(=O)C(=O)R10R11, -NR12C(=O)C(=O)NR10R11, -NR12C(=O)C(=O)Ora, -NR12SO2R10, -NR12C(=Y1)(CR14R15)nC(=Y2)NR10R11, -NR12C(=Y1)NR10C(=Y2)(CR14R15)nR11, - NR12C(=Y1)(CR14R15)nC(=Y2)(CR14R15)mR10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, -SC(=Y)OR10, -SC(=Y)NR10R11, alquilo C1- 12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, donde dichos alquilo, alquenilo, alquinilo, cicloalquilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, OH, alquilo C1-12, oxo, NR10R11, -C(=Y)NR10R11 y(CR14R15)n-arilo; R10, R11 y R12 son independientemente H, ORa, alquilo C1-12, alquenilo C2-8, o alquinilo C2-8, o carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20 monocíclicos o bicíclicos donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, SO2RC, CN, ORa, NRaRb, C(=O)NRaRb, CRaC(=O)Rb, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-20, arilo C6-20, y heteroarilo C1-20, o R10 y R11 conjuntamente con el nitrogeno al cual están unidos forman opcionalmente un anillo heterocíclico C3-20 saturado, parcialmente insaturado o totalmente insaturado que contiene opcionalmente uno o más átomos de anillos adicionales seleccionados entre N, O o S, donde dicho anillo heterocíclico está sustituido opcionalmente con uno o más grupos seleccionados independientemente entre oxo, ORa NRaRb, CF3, F, CI, Br, I, SO2Ra, C(=O)Ra, NR10C(=Y)R11, C(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, R13 es H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, (CR14R15)n-cicloalquilo, -(CR14R15)n-heterocicliIo, (CR14R15)n-arilo, (CR14R15)n-heteroarilo, (CR14R15)n-O-(CR14R15)m-arilo, (CR14R15)n-OR10, (CR14R15)n- NR10R11, (CR14R15)n-NR10C(=O)R11, o (CR14R15)n-NR10(SO2Me)-R11, donde dichas porciones alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, y heteroarilo están sustituidas opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, oxo, SO2RC, CN, ORa, C(=O)Ra, C(=O)ORa, NRaRb, NRaC(=O)Rb, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20; R14 y R15 son independientemente H, alquilo C1-12, o (CR14R15)tariIo, o R14 y R15 conjuntamente con los átomos a los cuales están unidos forman un anillo carbocíclico C3-12 saturado o parcialmente insaturado; o R10 y R15 conjuntamente con los átomos a los cuales están unidos forman un anillo heterocíclico C1-20 saturado o parcialmente insaturado que está opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, ORa, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20, donde dichos alquilo y arilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, y I, o R14 es nulo y R10 y R15 conjuntamente con los átomos a los cuales están unidos forman un anillo heteroarilo C1-20 que tiene uno o más heteroátomos; Ra y Rb son independientemente H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20, donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos alquilo o halogeno; Rc es alquilo C1-12 o arilo C6-20, donde dichos alquilo y arilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, ORa y C(=O)NRaRb; Y, Y1 y Y2 son independientemente O o S; t es 1,2,3,4,5 o 6;y n y m son independientemente 0, 1, 2, 3, 4, 5 o 6.
ARP070100391A 2006-01-30 2007-01-30 Compuestos heterobiciclicos de tiofeno y metodos de uso AR059246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76341406P 2006-01-30 2006-01-30

Publications (1)

Publication Number Publication Date
AR059246A1 true AR059246A1 (es) 2008-03-19

Family

ID=39272752

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100391A AR059246A1 (es) 2006-01-30 2007-01-30 Compuestos heterobiciclicos de tiofeno y metodos de uso

Country Status (8)

Country Link
US (1) US8003662B2 (es)
EP (1) EP1989211A2 (es)
JP (1) JP2009526761A (es)
CN (1) CN101522687A (es)
AR (1) AR059246A1 (es)
CA (1) CA2636242A1 (es)
TW (1) TW200806675A (es)
WO (1) WO2008063202A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0307077A2 (pt) * 2002-01-22 2017-06-20 Biomatera Inc método para secar polímeros biodegradáveis
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
BRPI0610322B8 (pt) 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2007240568A1 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2007146824A2 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
CN101541783B (zh) * 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
MX2010002427A (es) 2007-08-29 2010-03-30 Methylgene Inc Inhibidores de actividad de la proteina tirosina cinasa.
KR101608096B1 (ko) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암을 위한 그의 용도
PE20091624A1 (es) 2008-03-03 2009-11-19 Takeda Pharmaceutical Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina
AR070539A1 (es) * 2008-03-05 2010-04-14 Methylgene Inc Inhibidores de la actividad de proteina tirosina quinasa
MX2010009669A (es) * 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
WO2010126914A1 (en) * 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
BR112012004843A2 (pt) * 2009-09-03 2019-09-24 Allergan Inc compostos como moduladores de tirosina cinase
US8258158B2 (en) * 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
AU2011245248B2 (en) 2010-04-29 2016-01-07 Deciphera Pharmaceuticals, Llc Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites
TW201204733A (en) * 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
WO2014038881A2 (ko) * 2012-09-06 2014-03-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
US9574135B2 (en) * 2013-08-22 2017-02-21 Nanoco Technologies Ltd. Gas phase enhancement of emission color quality in solid state LEDs
KR20160137599A (ko) 2014-03-24 2016-11-30 제넨테크, 인크. C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
CN106232118A (zh) 2014-04-25 2016-12-14 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
US20190262323A1 (en) * 2016-10-31 2019-08-29 Georgetown University Compositions and methods for treating neurodegenerative disorders
KR102604900B1 (ko) 2017-05-11 2023-11-21 브리스톨-마이어스 스큅 컴퍼니 Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜
CN109206435B (zh) * 2017-06-29 2020-09-08 中国医药研究开发中心有限公司 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
CN111295386B (zh) * 2018-03-08 2022-09-06 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
EP3883935A4 (en) 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMA STORAGE DISEASES
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
EP4011885A4 (en) * 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
KR20220059386A (ko) * 2019-09-06 2022-05-10 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
WO2021139717A1 (zh) * 2020-01-07 2021-07-15 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
US20240002394A1 (en) * 2020-11-24 2024-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Deuterium-modified thienopyridone compound
CN115745999A (zh) * 2021-11-19 2023-03-07 浙江奥洋新材料有限公司 一种可提高反应活性的纤维素碱性醚化、酯化反应溶剂叔丁五元二环胍的结构及其合成路线
CN117209474A (zh) * 2022-06-10 2023-12-12 成都百裕制药股份有限公司 吡咯烷衍生物、药物组合物及其在医药上的应用
CN115177618A (zh) * 2022-07-26 2022-10-14 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Flt3抑制剂在制备治疗急性髓系白血病药物中的应用
CN118894838B (zh) * 2024-07-11 2025-09-02 深圳技术大学 一种酰胺衍生物及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100287A3 (en) 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
ES2223827T3 (es) 2000-06-06 2005-03-01 Pfizer Products Inc. Derivados de tiofeno utiles como agentes anticancerigenos.
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
CA2454538A1 (en) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
US20050009845A1 (en) 2001-12-19 2005-01-13 Caferro Thomas R. Thienopyrimidine compounds as protein tyrosine kinase inhibitors
WO2003074529A2 (en) 2002-03-01 2003-09-12 Pfizer Inc. iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
EP1548008A4 (en) 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
CA2536788A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
JP2007504122A (ja) 2003-08-29 2007-03-01 ファイザー・インク 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
JPWO2005080377A1 (ja) * 2004-02-20 2007-10-25 キリンホールディングス株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
BRPI0513982A (pt) * 2004-07-30 2007-11-27 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-MET MODULATORS MODULATORS AND METHODS OF USE
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (pt) 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2008054674A2 (en) * 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds

Also Published As

Publication number Publication date
WO2008063202A2 (en) 2008-05-29
JP2009526761A (ja) 2009-07-23
CA2636242A1 (en) 2008-05-29
TW200806675A (en) 2008-02-01
CN101522687A (zh) 2009-09-02
US8003662B2 (en) 2011-08-23
WO2008063202A3 (en) 2009-01-22
EP1989211A2 (en) 2008-11-12
US20070197537A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
AR059246A1 (es) Compuestos heterobiciclicos de tiofeno y metodos de uso
AR059887A1 (es) Compuestos pirazolicos heterobiciclicos, composiciones farmaceuticas que los contienen, y usos en trastornos hiperproliferativos, tales como cancer
AR060632A1 (es) Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
AR050788A1 (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
AR053728A1 (es) Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20210040A1 (es) Moduladores de la via de estres integrada
CO5011121A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
AR067093A1 (es) N-(2-(hetaril) arilsulfonamidas y n-(2-( heteraril) hetaril) arilsulfonamidas
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
PE20250155A1 (es) Derivados de la urea que pueden ser utilizados para tratar el cancer
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
AR050529A1 (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
AR064154A1 (es) Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
PE20061367A1 (es) Nuevos derivados del fluoreno y composiciones que los contienen
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
AR070521A1 (es) Derivados de 4h-pirido[4,3-d]-pirimidin-4-ona,inhibidores de quinasas,composiciones farmaceuticas que los contienen,uso de los mismos para el tratamiento de enfermedades con proliferacion celular o autoinmunes y metodo de preparacion de intermediarios de sintesis .
AR068898A1 (es) Compuestos de tienopirimidinas y pirazolopirimidina y su uso como inhibidores de mtor y pi3k

Legal Events

Date Code Title Description
FB Suspension of granting procedure